Modality
Multispecific
MOA
BCL-2i
Target
Tau
Pathway
Innate Imm
Parkinson'sMigraineAngelman
Development Pipeline
Preclinical
~Dec 2012
→ ~Mar 2014
Phase 1
~Jun 2014
→ ~Sep 2015
Phase 2
~Dec 2015
→ ~Mar 2017
Phase 3
~Jun 2017
→ ~Sep 2018
NDA/BLA
Dec 2018
→ Mar 2029
NDA/BLACurrent
NCT07109655
2,815 pts·Angelman
2018-12→TBD·Terminated
NCT03643580
1,884 pts·Angelman
2023-04→2029-03·Recruiting
4,699 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-03-133.0y awayPh3 Readout· Angelman
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
NDA/BLA
Termina…
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2029-03-13 · 3.0y away
Angelman
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07109655 | NDA/BLA | Angelman | Terminated | 2815 | EDSS |
| NCT03643580 | NDA/BLA | Angelman | Recruiting | 1884 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 | |
| Zanumavacamten | Iovance | Phase 2 | FLT3 |